Skip to main content
This website uses cookies. By continuing to use this website you are agreeing to our use of cookies as described in our privacy policy.
Bulletin

Recent shift of Québec physicians: The Collège Revises its Position in Connection With Cannabis Prescription

Fasken
Reading Time 4 minute read

Life Sciences and Health Bulletin

As of June 2018, approximately 331,000 Canadians were registered clients of a licensed medical cannabis producer. Despite this large number, only 9,700 were registered clients in Québec. In comparison, during the same period, the number rose to 143,000 in Ontario. This contrast can be explained in part by the close supervision by the Collège des médecins du Québec ("Collège") of the use of cannabis for therapeutic purposes.

With the legalization of cannabis for recreational purposes at its doorstep, the Collège des médecins issued new directives for Québec physicians in September 2018. These directives replace the previous directives from 2014, seen by many as rather conservative, and imposes a shift in medical standards that could have a significant impact on the way medical cannabis is seen in Quebec.

* * *

A study of both directives points to a change in the approach advocated by the Collège regarding the use of cannabis for medical purposes.

2014 directives for prescribing dried cannabis for medical purposes

In response to the previous Marihuana for Medical Purposes Regulations, which allowed the prescription of cannabis, an unapproved product, the Collège des médecins circumscribed its use.

Notably, the Directives for prescribing dried cannabis for medical purposes [French only] from April 2014:

  • Criticized the absence of approval normally required for marketing a prescription drug;
  • Qualified the therapeutic use of cannabis for treatment not recognized under the Code of Ethics of Physicians, which essentially restricted its use to medical research;
  • Favoured the use of other forms of cannabinoids;
  • Established a strict medical verification protocol for patients before inclusion in a research project involving cannabis;
  • Prohibited physicians from providing cannabis to patients directly;
  • Prohibited physicians from becoming cannabis producers.

As a result, since 2014, the Collège has recommended limiting the prescription of cannabis to patients participating in a research project. The Collège des médecins’s approach was based on caution and lack of scientific consensus on the product’s effects. The Collège did not seem to consider cannabis as a recognized treatment or medical solution.

2018 directives for prescribing cannabis for medical purposes

As the legalization of cannabis for recreational purposes approached, and considering the scientific data now available, the Collège has chosen to revise its position on the use of cannabis in the medical field and its prescription by physicians in Quebec.

The new Directives for prescribing cannabis for medical purposes [French only] from September 2018:

  • Now allow cannabis to be prescribed for medical purposes outside of a research project;
  • Provide for the use of cannabis only in medically necessary cases;
  • Require physicians to weigh the therapeutic benefits of a therapeutic cannabis prescription against the potential adverse effects;
  • Provide for the therapeutic use of cannabis only as a subsidiary solution to the usual treatments;
  • Establish warnings for certain groups of people at risk (people under 25, people at risk of addiction or cardiovascular disease, etc.);
  • Provide the need for a complete, in-person medical assessment before providing a prescription;
  • Impose on physicians a duty to inform regarding the patient’s responsibility for the use and storage of the product;
  • Impose a progressive dosage treatment;
  • Require physicians to disclose their financial interests in a cannabis business.

In sum, the new directives’ approach now views cannabis as a potential treatment. Although it remains only an alternative to traditional treatments and caution remains in place, there is still a significant change in the Collège’s position on the therapeutic use of cannabis in Quebec.

This paradigm shift is due in part to the emergence of new scientific data on the use of cannabis for medical purposes and the anticipated rise in insurers' requests to physicians to justify the reimbursement of cannabis administered for medical reasons.

Although this mindset change in the therapeutic use of cannabis is manifested through a Collège directive, it is heralding much larger changes. While the legalization for recreational use by adults certainly removed some stigmatization traditionally associated with cannabis, one might think that using cannabis as a fully-fledged treatment will liberalize its use even more.

It remains to be seen whether producers, patients, insurers, health professionals and all other players in the therapeutic cannabis market will feel the real repercussions of these changes following the legalization that occurred on October 17, 2018.

... is medicinal cannabis here to stay?